Personalizing Prostate Specific Antigen Testing May Improve Specificity, Reduce Biopsies

Technique relies on correcting for genetic variants, reported in The Journal of Urology®

New York, NY, April 14, 2013

Genetic variants have been identified which can increase serum prostate specific antigen (PSA) concentrations and prostate cancer risk. A new study published in The Journal of Urology® reports that correcting PSA levels for these genetic variants can have significant consequences, including avoiding unnecessary biopsies for some men and eliminating false complacency for others.

In this study of 964 healthy Caucasian men, correcting individual PSA levels for these genetic variants led to an 18.3 percent reduction in the number of men who initially had a measured serum PSA above the biopsy criteria, but whose adjusted PSA fell below the cutoff value. The latter group would have likely undergone what would have been an unnecessary biopsy. Conversely, genetic correction led to PSA levels moving from below threshold to above threshold for 3.4 percent of the men, thus sending out an alert for further investigation.

“If our results are validated, adjustment for the four PSA single nucleotide polymorphisms (SNPs) could potentially prevent up to 15 percent to 20 percent of prostate biopsies. Since it has been estimated that more than 1 million biopsies are performed in the United States annually, this could translate into 150,000 to 200,000 potentially unnecessary biopsies every year,” says William J. Catalona, MD, professor of urology at the Feinberg School of Medicine of Northwestern University. In addition to cost savings, fewer biopsies mean fewer adverse outcomes, such as infection, sepsis, and hospitalization.

For 98 percent of the men, genetic adjustment of PSA levels did not change outcome. However, genetic correction was important for the 17 men who were reclassified as no longer meeting biopsy criteria of PSA 2.5 ng/ml or greater and the three whose condition was up classified. The results suggest that traditional single cutoff PSA screening levels of 2.5 ng/ml or greater or 4.0 ng/ml or greater should be personalized to reflect an individual’s genetic make-up.

“If confirmed, this approach could potentially be used to tailor PSA screening, possibly reducing unnecessary biopsies and avoiding delay in performing necessary biopsies,” concludes Dr. Catalona and his co-investigators.

# # #

Notes for Editors
“Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies,” by Brian T. Helfand, Stacy Loeb, Qiaoyan Hu, Phillip R. Cooper, Kimberly A. Roehl, Barry B. McGuire, Nikola A. Baumann and William J. Catalona. DOI: http://dx.doi.org/10.1016/j.juro.2012.12.023. The Journal of Urology, Volume 189, Issue 5 (May 2013) published by Elsevier.
Full text of the article is available to credentialed journalists upon request; contact Linda Gruner at +1 212 633 3923 or jumedia@elsevier.com to obtain copies. To schedule an interview with the authors contact William J. Catalona, MD, Professor of Urology, Director, Clinical Prostate Cancer Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, at +1 312 695 4471 or WCatalona@nmff.org.

About the Authors
Brian T. Helfand, Division of Urology, Northshore University Healthcare System, Evanston

Stacy Loeb, Department of Urology, New York University, New York, New York

Qiaoyan Hu, Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago

Phillip R. Cooper, Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago

Kimberly A. Roehl, Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago

Barry B. McGuire, Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago

Nikola A. Baumann, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota

William J. Catalona, Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago

About The Journal of Urology®
Established in 1917, The Journal of Urology (www.jurology.com) is the official journal of the American Urological Association (www.auanet.org). It is the most widely read and highly cited journal in the field. It brings to its readership all the clinically relevant information needed to stay at the forefront of this dynamic field. This top-ranking journal presents investigative studies on critical areas of research and practice, survey articles providing short condensations of the best and most important urology literature worldwide and practice-oriented reports on interesting clinical observations.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Linda Gruner
Elsevier
+1 212 633 3923
jumedia@elsevier.com